×
ZIVO Bioscience Common Stock Net 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ZIVO Bioscience common stock net from 2016 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
ZIVO Bioscience Common Stock Net 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
ZIVO Bioscience common stock net from 2016 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$168.1B
Vertex Pharmaceuticals (VRTX)
$119.2B
Regeneron Pharmaceuticals (REGN)
$113.7B
Gilead Sciences (GILD)
$102.4B
Bristol Myers Squibb (BMY)
$101.3B
CSL (CSLLY)
$95.4B
GSK (GSK)
$84.1B
Alnylam Pharmaceuticals (ALNY)
$35B
Argenex SE (ARGX)
$32.8B
Biogen (BIIB)
$27.5B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$24.5B
BeiGene (BGNE)
$20.1B
Illumina (ILMN)
$20.1B
Genmab (GMAB)
$15.8B
BioMarin Pharmaceutical (BMRN)
$13.1B
Vaxcyte (PCVX)
$12.7B
Exact Sciences (EXAS)
$12.5B
Insmed (INSM)
$12.5B
Incyte (INCY)
$12.2B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.5B
Legend Biotech (LEGN)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B
Repligen (RGEN)
$7.8B
Exelixis (EXEL)
$7.4B